Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2000 participants
OBSERVATIONAL
2014-09-12
2035-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PREVENT ALL ALS Study
NCT06581861
Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders
NCT05474235
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
NCT01495390
ASSESS ALL ALS Study
NCT06578195
Amyotrophic Lateral Sclerosis: A Multicenter Retrospective Observational Registry
NCT07143656
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Person living with ALS/MND
An adult over the age of 18, that has received a diagnosis of ALS or other Motor Neuron Disease from a practicing physician.
No interventions assigned to this group
Asymptomatic gene carrier
An adult over the age of 18 who does not have symptoms of ALS and carries a mutation known to be associated with ALS
No interventions assigned to this group
Healthy Volunteer
An adult over the age of 18 who does not have any biological connection to ALS or other Motor Neuron Disease, and no significant health problems.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Can communicate in written English
* Has a diagnosis of ALS/MND or is a known carrier of an ALS associated mutation
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ALS Therapy Development Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fernando G Vieira, M.D.
Role: PRINCIPAL_INVESTIGATOR
ALS Therapy Development Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ALS Therapy Development Institute
Watertown, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Straczkiewicz M, Burke KM, Calcagno N, Premasiri A, Vieira FG, Onnela JP, Berry JD. Free-living monitoring of ALS progression in upper limbs using wearable accelerometers. J Neuroeng Rehabil. 2024 Dec 21;21(1):223. doi: 10.1186/s12984-024-01514-7.
Gupta AS, Patel S, Premasiri A, Vieira F. At-home wearables and machine learning sensitively capture disease progression in amyotrophic lateral sclerosis. Nat Commun. 2023 Aug 21;14(1):5080. doi: 10.1038/s41467-023-40917-3.
Vieira FG, Venugopalan S, Premasiri AS, McNally M, Jansen A, McCloskey K, Brenner MP, Perrin S. A machine-learning based objective measure for ALS disease severity. NPJ Digit Med. 2022 Apr 8;5(1):45. doi: 10.1038/s41746-022-00588-8.
Related Links
Access external resources that provide additional context or updates about the study.
ARC Sign Up Page
ARC Data Commons Inquiry Page - for researcher access to ARC data
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALSTDI0103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.